The human kallikreins are a cluster of 15 kallikreins and kallikrein-related peptidases (KLKs). Evidence shows the involvement of KLKs in a wide range of pathophysiological processes, and underscores their potential contribution to cancer, skin and neurodegenerative disorders. The control of KLK expression is not fully elucidated. Understanding the mechanisms controlling KLK expression is an essential step towards exploring the pathogenesis of several diseases and the use of KLKs as disease biomarkers and/or therapeutic targets. Recently, epigenetic changes (including methylation, histone modifi cation and microRNAs [miRNAs]) have drawn attention as a new dimension for controlling KLK expression. Reports showed the effect of methylation on the expression of KLK genes. This was also shown to have potential utility as a prognostic marker in cancer. miRNAs are small RNAs that control the expression of their targets at the post-transcriptional level. Target prediction showed that KLKs are potential targets of miRNAs that are dysregulated in tumors, including prostate, kidney and ovarian cancers, with downstream effect on tumor proliferation. Experimental validation remains an essential step to confi rm the KLK-miRNA interaction. Epigenetic regulation of KLKs holds promise for an array of therapeutic applications in many diseases including cancer.
Introduction
The kallikrein-related peptidases (KLKs) are a family of 15 serine proteases that exist as a large gene cluster on chromosome 19q13.4 . KLKs have been implicated in multiple physiological pathways including cell proliferation, differentiation and apoptosis, semen liquefaction, skin desquamation, innate immunity, neurodegeneration and extracellular matrix remodeling (Clements , 2008 ; Sotiropoulou et al. , 2009 ) . One of the most wellcharacterized KLKs is prostate-specifi c antigen (PSA; KLK3), which is the most valuable biomarker for diagnosis and monitoring of prostate cancer Mavridis and Scorilas , 2010 ) . Other KLKs have also been investigated as potential biomarkers, as they are dysregulated in various cancers including ovarian, breast, testicular and renal cancers Emami and Diamandis , 2008 ) . Understanding the regulatory mechanisms of this family of proteases can thus provide important information on cancer pathogenesis.
KLK activity is regulated at multiple levels including transcriptional, translational and post-translational modifi cations (Yousef et al. , 2005 ; Emami and Diamandis , 2008 ) . Recently, accumulating evidence led to the hypothesis that epigenetic changes can also play a critical role in KLK gene regulation. Evidence to support this hypothesis includes the co-expression of many KLKs in the same tissues (Shaw and Diamandis , 2007 ) , the parallel dysregulation of multiple KLKs in cancer and other diseases (Paliouras et al. , 2007 ; Sotiropoulou et al. , 2009 ) , the relatively short distances between adjacent KLK genes (which could be as short as 1.5 kilobases between KLK1 and KLK15 ) (Yousef et al. , 2000 ) , the absence of a classic promoter sequence in many KLK genes (Chow et al. , 2008 ) , and the discrepancies observed in the expression pattern of many KLK genes between the mRNA and protein levels (Shaw and Diamandis , 2007 ) . Preliminary evidence support the hypothesis that KLKs can be epigenetically modifi ed, leading to their altered roles in normal and disease pathophysiology (Bharaj et al. , 2002 ; Sidiropoulos et al. , 2005 ; White et al. , 2010a ) .
Epigenetic changes are heritable modifi cations that do not involve a change in DNA sequence, and include DNA methylation, histone modifi cation, and microRNA (miRNA)-mediated gene silencing. These changes have evolved to allow the stable inheritance of gene activity states from one generation to the next, thus defi ning the identity and proliferation potential of different cells to give them unique morphological and functional properties (Herceg and Ushijima , 2010 ) . Furthermore, epigenetic changes can protect cells from endoparasitic sequences, and maintain imprinting and X-chromosome expression patterns within a specifi c tissue type (Bird , 2002 ; Ballestar and Esteller , 2005 ) . Epigenetic mechanisms ensure that some genes or genome regions are inherited in a transcriptionally active state (open chromatin conformation known as ' euchromatin ' ), while others adopt a highly condensed, transcriptionally inactive form (closed chromatin conformation known as ' heterochromatin ' ). Consistent with their key roles in gene regulation, it has been shown that dysregulation of epigenetic mechanisms is closely linked to human diseases, including cancer. The loss of the original identity of cells is thought to play a key role in tumorigenesis and cancer progression (Feinberg and Tycko , 2004 ; Ballestar and Esteller , 2005 ; Herceg and Ushijima , 2010 ) . The purpose of this review is to outline the known mechanisms of epigenetic regulation and to describe how aberrations in these mechanisms can contribute to cancer pathogenesis, with particular emphasis on the KLK gene family.
Classes of epigenetic modifi cations and their relation to cancer

DNA methylation
The best-studied mechanism of epigenetic regulation in eukaryotes is DNA methylation. This refers to the covalent addition of a methyl or hydroxymethyl group to the 5-carbon position of cytosines located 5 ′ to guanosine residues (Ballestar and Esteller , 2005 ; Herceg and Ushijima , 2010 ) . Approximately 3 -5 % of all cytosine residues in the human genome are methylated (Ehrlich et al. , 1982 ) . Enzymes known as DNA cytosine methyltransferases (DNMTs) are responsible for these modifi cations (Li et al. , 1993 ; Okano et al. , 1999 ; Ballestar and Esteller , 2005 ) , which usually occur in CG-rich clusters of the genome known as ' CpG islands ' (Bird , 1986 ) . CpG islands are approximately 0.5 -2.0 kilobases in length, they mainly occur near the promoters and regulatory regions of protein-coding genes, and are normally unmethylated (Bird , 1986 ; Ballestar and Esteller , 2005 ) . DNA methylation has been associated with a transcriptionally inactive state of chromatin, suggesting it is an important mechanism of gene regulation (Ballestar and Esteller , 2005 ) . Generally, increased methylation ( ' hypermethylation ' ) results in the organization of chromatin into heterochromatin, while decreased methylation ( ' hypomethylation ' ) produces euchromatin (Herceg and Ushijima , 2010 ) .
Evidence suggests that CpG island hypermethylation is the major epigenetic alteration in the development of cancer (Esteller , 2002 ; Feinberg and Tycko , 2004 ; Jones and Baylin , 2007 ) . Hypermethylation renders gene promoters unable to bind transcription factors, with subsequent gene inactivation. This has been demonstrated to occur in genes like tumor suppressor genes, cell cycle-related genes, DNA mismatch repair genes, hormone receptors, and tissue or cell adhesion molecules (Merlo et al. 1995 ; Herman et al. , 1998 ; Jones and Laird , 1999 ; Simpkins et al. , 1999 ; Baylin et al. , 2001 ; Yan et al. , 2001 ) . Dysregulation of these genes can lead to increased levels of genetic damage, predisposing cells to later genetic instability, which can contribute to tumor progression (Yan et al. , 2001 ; Strathdee and Brown , 2002 ; Sidiropoulos et al. , 2005 ) . Other hypotheses for how DNA methylation may be dysregulated in cancer include increased expression of DNMTs, and the failure of mechanisms that control or prevent methylation of CpG islands in normal cells (Ballestar and Esteller , 2005 ) . Comprehensive analysis of methylation in many different tumor types and gene promoters has revealed that CpG island hypermethylation can be specifi c to tumor type (Ballestar and Esteller , 2005 ) . In fact, analysis of hypermethylated CpG islands may be powerful enough to classify tumors of unknown origin (Paz et al. , 2003 ) .
Histone modifi cation
Histones are the main protein components of chromatin and can undergo post-translational modifi cations to determine whether chromatin is in the heterochromatin or euchromatin form. Histone modifi cations work together with other epigenetic mechanisms to establish and maintain gene activity states for the regulation of a wide range of cellular processes like gene transcription, DNA replication, and DNA repair (Kouzarides , 2007 ; Sawan and Herceg , 2010 ) . Various covalent (and reversible) changes occur including acetylation, methylation, phosphorylation, and ubiquitination.
Histone acetylation occurs at lysine residues of exposed N-terminal tails of a histone octamer by the action of histone acetyltransferases (HATs) (Eberharter and Becker , 2002 ) . Modifi cation of charged lysine residues leads to a loss of positive charge, resulting in reduced affi nity between histones and DNA (Steger and Workman , 1996 ) . This destabilizes the nucleosome and chromatin structure, which facilitates access of nuclear factors to DNA to induce transcription (Workman and Kingston , 1998 ; Strahl and Allis , 2000 ; Eberharter and Becker , 2002 ) . Thus, hyperacetylation of histones is considered a hallmark of transcriptionally active chromatin (Sawan and Herceg , 2010 ) . This is reversed by histone deacetylases (HDACs), which remove acetyl groups, decreasing the space between the nucleosome and the DNA, leading to a heterochromatin-like conformation. This diminishes accessibility for transcription factors and promotes transcriptional repression (Rundlett et al. , 1996 ; Walkinshaw et al. , 2008 ) . HDACs are also thought to be recruited as part of a co-repressor complex in response to DNA methylation, and have also been shown to recruit DNMTs (Robertson et al. , 2000 ; Fuks et al. , 2001 ) .
Histone methylation occurs on the side-chain nitrogen atoms of lysine and arginine residues of histones by protein arginine methyltransferases (PRMTs) and histone methyltransferases (HMTs), with histone H3 being the most highly methylated histone (Sawan and Herceg , 2010 ) . Both arginine methylation and lysine methylation have been associated with gene activation and silencing, but this is highly dependent on the residue that is methylated and whether or not it is mono-, di-, or tri-methylated (Bauer et al. , 2002 ; Metzger et al. , 2005 ; Richard et al. , 2005 ; Yamagata et al. , 2008 ; Zhao et al. , 2009 ; DiTacchio et al. , 2011 ) .
Histone phosphorylation occurs through the action of various kinases, and has been linked to gene activation in different cellular processes such as transcription, mitosis, DNA repair, apoptosis, and chromosome condensation (Mahadevan et al. , 1991 ; Cheung et al. , 2000 ) . The action of phosphatases reverses this process, and results in transcriptional inhibition (Nowak and Corces , 2004 ) .
Histone ubiquitination occurs at lysine residues by a number of ubiquitinating enzymes, mainly on histones H2A and H2B and is associated with both transcriptional activation and silencing (Zhang , 2003 ) , depending on the genomic context (Zhu et al. , 2005 ; Wang et al. , 2006 ) . Furthermore, ubiquitinated histones can signal the recruitment of other regulatory molecules for subsequent histone modifi cations (Briggs et al. , 2002 ) . Additional control of transcriptional regulation occurs through the action of ubiquitin proteases, which deubiquitinate histones (Henry et al. , 2003 ; Kodadek , 2010 ) . All of the above modifi cations are maintained with high fi delity through cell division (Sawan and Herceg , 2010 ) . A level of complexity is added to transcriptional regulation by the ' histone code ' , a combination of different histone modifi cations that are read by different cellular machineries to dictate a variety of cellular outcomes (Strahl and Allis , 2000 ; Jenuwein and Allis , 2001 ) .
Many recent studies have implicated aberrant patterns of histone modifi cations and chromatin remodeling in a large number of human malignancies (Sawan and Herceg , 2010 ) . Deregulation of histone modifi cations may shift the balance of gene expression leading to alterations in critical cellular processes such as transcription, proliferation, apoptosis, and DNA repair, ultimately resulting in cellular transformation and tumorigenesis (Sawan and Herceg , 2010 ) . Mutations causing aberrant activity of several histone-modifying enzymes (HDACs, HMTs) have been identifi ed in leukemia, breast, and other sporadic cancers (Gayther et al. , 2000 ; Zhang et al. , 2004 ; Esteller , 2006 ; Ozdag et al. , 2006 ; Ropero et al. , 2006 ) and are believed to contribute to cancer development and progression (Sawan and Herceg , 2010 ) . Accumulating evidence indicates that different types and subtypes of cancer may have specifi c patterns of histone modifi cations ( ' signatures ' ), a phenomenon that can be exploited in biomarker discovery (Sawan and Herceg , 2010 ) (see later section). For example, some studies show that arginine methylation may play a role in expression of the genes involved in tumor suppression (Pal et al. , 2004 ; Singh et al. , 2004 ) .
Post-transcriptional regulation by miRNAs
Recently, the role of non-coding RNAs in the control of gene expression has been documented in the literature. miRNAs are small (20 -25 nucleotides) non-coding RNAs located either within the introns or exons of protein-coding genes or in intergenic regions, and are predicted to regulate expression of up to one-third of all human genes (Bartel , 2004 ) . They have been implicated in a variety of biological processes, including development, differentiation, apoptosis, and cell proliferation (Bartel , 2004 ; He and Hannon , 2004 ; Pasquinelli et al. , 2005 ; Esquela -Kerscher and Slack, 2006 ; Carleton et al. , 2007 ; Yousef , 2008 ) . This regulation is mediated by the direct interaction between miRNAs and mRNAs through an RNA-induced silencing complex (RISC) that can lead to either translational repression or mRNA degradation (Croce and Calin , 2005 ) .
Accumulating evidence indicates that deregulation of miRNAs is linked to cancer (He and Hannon , 2004 ; Croce and Calin , 2005 ; Calin and Croce , 2006 ; Esquela -Kerscher and Slack, 2006 ; Pampalakis et al. , 2006b ; Kulshreshtha et al. 2007 ; White et al. , 2011b ) . miRNAs can contribute to cancer pathogenesis in several ways. Experimental evidence has shown that miRNAs can act as either tumor suppressors or oncogenes in many cancers. Also, many miRNA genes are located in cancer-related hotspots and fragile sites that are frequently susceptible to either loss or amplifi cation (Calin et al. , 2004 ) . Finally, several recent studies showed that miRNA profi les differ signifi cantly between cancer and normal tissues and also between different tumor subtypes (White et al. , 2011a ,b; Youssef et al. , 2011 ) . Tumor-specifi c signatures of deregulated miRNAs with potential clinical implications have been identifi ed for many cancers including lymphoma (Navarro et al. , 2008 ) , colon cancer (Michael et al. , 2003 ) , glioblastoma (Chan et al. , 2005 ) , breast (Iorio et al. , 2005 ) , ovarian (Iorio et al. , 2007 ) , gastric (Ueda et al. , 2010 ) , pancreatic (Szafranska et al. , 2007 ) , and lung cancers (Takamizawa et al. , 2004 ) .
Interestingly, miRNAs can also be targets of epigenetic changes in cancer (Fabbri and Calin , 2010 ) , as their expression can be regulated by both DNA methylation and histone modifi cations (Lehmann et al. , 2008 ; Toyota et al. , 2008 ; Saito et al. , 2009 ) . It has been shown that hypermethylation of miRNA promoters is associated with metastasis (Lujambio et al. , 2007 ) . Furthermore, some miRNAs target, (directly or indirectly), the effectors of the epigenetic machinery like DNMTs (Fabbri et al. , 2007 ; Fabbri and Calin , 2010 ) and HDACs (Tuddenham et al. , 2006 ; Noonan et al. , 2009 ) to induce cell-cycle arrest, apoptosis, and a senescent-like phenotype. The potential clinical utility of miRNA as tumor markers and therapeutic targets has been recently reviewed (White et al. , 2011b ) .
Epigenetic regulation of the kallikrein-related peptidases
KLKs are known to be dysregulated in many cancer types. In this section, we discuss recent work to elucidate the mechanisms whereby epigenetic modifi cations may be involved in KLK regulation, and how these regulatory mechanisms may be altered in the cancer state.
KLK regulation by DNA methylation
Biocomputational and in silico analyses have identifi ed that the KLK gene locus contains 16 CpG islands in eight KLK genes (Pampalakis et al. , 2006b ). These include CpG islands upstream or in the exon-intron sequences of KLK15 , KLK2 , KLK4 , KLK5 , KLK10 , KLK11 , KLK13 and a CpG island downstream of KLK1 . KLK5 and KLK10 have the most CpG islands (each associated with four CpG islands), followed by KLK15 (two CpG islands) and the rest of the abovementioned KLK genes with one CpG island each. Among these CpG islands, the largest one is found in the third exon of KLK10 while the smallest is located in intron 5 of KLK11 . Many of the CpG islands within the KLK gene locus are not located in promoter regions. However, it has been demonstrated that exonic CpG island hypermethylation can occur irrespective of methylation of the associated promoter and may still lead to gene inactivation (El -Naggar et al., 1997 ; Li et al. , 2001 ) .
The presence of CpG islands in certain KLK genes suggests that DNA methylation plays an important role in transcriptional regulation of these genes, and that the well-established cancer-associated decreased expression or complete inactivation of these KLK genes may be the result of CpG island hypermethylation. A number of studies have investigated the relationship between KLK gene methylation and expression using 5-aza-2 ′ -deoxycytidine (5-aza-dC), a cytosine analog that reduces DNA methylation. These studies have demonstrated that treating cell lines derived from hepatocellular carcinoma, prostate, breast, ovarian, cervix, gastric and lung cancer, with 5-aza-dC can induce the expression of KLK genes 1, 5, 6, 10, 11, 12 and 13; thus establishing that DNA methylation plays a role in regulating their expression (Li et al. , 2001 ; Roman -Gomez et al., 2004 ; Sidiropoulos et al. , 2005 ; Pampalakis et al. , 2006b ; Pampalakis and Sotiropoulou , 2006a ; Huang et al. , 2007 ; Kioulafa et al. , 2009 ; Lu et al. , 2009 ; Pampalakis et al. , 2009 ; Zhang et al. , 2010 ; Chou et al. , 2011 ; Wong et al. , 2011 ) . Interestingly, KLK6 has been included in these studies although it does not contain a CpG island. However, the promoter of this gene contains a suffi cient number of CpG dinucleotides to perform DNA methylation analysis and it was found that KLK6 promoter methylation is associated with the downregulation of gene expression in breast cancer (Pampalakis and Sotiropoulou , 2006a ; Pampalakis et al. , 2009 ) .
The CpG island in the third exon of KLK10 has been most extensively investigated and its hypermethylation status has been examined in patient specimens and cell lines from different cancers including acute lymphoblastic leukemia, nonsmall cell lung cancer, hepatocellular carcinoma, breast, ovarian, prostate, lung, and gastric cancers. The fi rst evidence that KLK10 expression may be regulated by DNA methylation was provided by Li et al. in 2001 . In this study, it was demonstrated that the CpG island within exon 3 of KLK10 is methylated in breast cancer cell lines and a small number of primary breast cancer tumors, and correlates with loss of KLK10 expression (Li et al. , 2001 ). Additionally, it was demon strated that treatment of KLK10 non-expressing cells with 5-aza-dC restored its expression, indicating a causal role of methylation in the loss of KLK10 expression. Since then, two additional studies have investigated KLK10 exon 3 methylation in breast cancer and confi rmed that the hypermethylation of this CpG island plays an important role in the downregulation of KLK10 mRNA and protein expression Kioulafa et al. , 2009 ). In addition, tumor-specifi c KLK10 exon 3 hypermethylation has been found to be an independent prognostic factor for disease relapse and diseaserelated death (Kioulafa et al. , 2009 ) . Similarly, KLK10 exon 3 methylation was signifi cantly associated with gene expression and shorter disease-free survival in both childhood and adult acute lymphoblastic leukemia (Roman -Gomez et al., 2004 ) . KLK10 exon 3 hypermethylation is also associated with gene expression in non-small cell lung cancers and was found to be an independent prognostic biomarker of advanced and lymph node metastatic disease (Huang et al. , 2007 ) .
Hypermethylation of KLK 10 exon 3 was also found in hepatocellular carcinoma on a CpG microarray platform and was later validated in a larger series of samples (Lu et al. , 2009 ). Further, it was found to be signifi cantly associated with cirrhosis and hepatitis C virus infection in hepatocellular carcinoma. Importantly, studies have demonstrated that exon 3 methylation refl ects hypermethylation within the promoter and untranslated regions in the gene in acute lymphoblastic leukemia and more recently KLK10 5′ UTR hypermethylation in prostate cancer tissues has been noted on a microarray platform (Roman -Gomez et al., 2004 ; Kobayashi et al. , 2011 ) . Interestingly, CpG island hypomethylation has been shown to occur in KLK13 during lung cancer development and progression (Chou et al. , 2011 ) . The KLK13 promoter CpG island was found hypermethylated in normal lung cell lines, moderately methylated in low-invasive cell lines and hypomethylated in high-invasive cell lines. Table 1 A summarizes the studies showing epigenetic regulation of KLK genes by methylation.
KLK regulation by histone modifi cation
Many KLKs are known to be regulated by steroid hormones in a subset of tissues. Steroid hormones bind to response elements in the promoters of target genes, suggesting that open chromatin conformation is necessary for the transcriptional activation of these KLKs. However, very little is known about the role of histone modifi cations in the regulation of KLK gene expression or the implications for cancer pathogenesis. Kang et al. and Jia et al. have investigated histone modifications in association with androgen regulation of KLK2 and KLK3 genes in prostate cancer cell lines (Kang et al. , 2004 ; Jia et al. , 2006 ) . It was found that activation of the KLK2 and KLK3 genes by androgens in the androgen-sensitive LNCaP cells is linked to a cascade of distinct covalent histone modifi cations including accumulation of lysine 9 and 14 diacetylation in histone H3, increased phosphorylation of serine 10 in H3 and increased di-and tri-methylation of lysine 4 in H3. Further, it was found that androgen-independent cell lines had a signifi cantly increased lysine 9 and 14 acetylation and lysine 4 methylation in H3 at the KLK3 locus compared to androgen-dependent cells contributing to increases receptiveness to gene transcription.
Other studies investigated the role of histone deacetylation in the silencing of KLK6 in breast cancer (Pampalakis and Sotiropoulou , 2006a ; Pampalakis et al. , 2009 ) . They found that constitutive and inducible expression of KLK6 positively correlated with histone H4 acetylation located in KLK 6 upstream sequences. To confi rm this, KLK6 nonexpressing MDA-MB-231 breast cancer cells were treated with trichostatin A, an HDAC inhibitor. Following treatment, KLK10 exon 3 correlates with shorter disease-free survival in both childhood and adult acute lymphoblastic leukemia. Sidiropoulos et al. , 2005 KLK10 exon 3 hypermethylation is associated with the downregulation of KLK10 mRNA and protein expression in breast, ovarian and prostate cancer cell lines. Pampalakis et al. , 2006b Published a map of the 16 CpG islands in the kallikrein locus. Additionally, KLK5 , KLK11 and KLK12 methylation is found to be correlated with gene expression in breast and prostate cancer cell lines. Pampalakis and Sotiropoulou , 2006a ; Pampalakis et al. , 2009 KLK6 promoter methylation is associated with the downregulation of the gene in breast cancer cell lines and a small number of patients. Huang et al. , 2007 Treatment of KLK10 non-expressing gastric cancer cell lines with a demethylating agent leads to re-expression of the gene. Kioulafa et al. , 2009 Tumor-specifi c KLK10 exon 3 hypermethylation is an independent prognostic factor for disease relapse and disease-related death in early breast cancer patients. Lu et al. , 2009 KLK10 exon 3 cpG Island is hypermethylated in hepatocellular carcinoma and is signifi cantly associated with cirrhosis and hepatitis C virus infection. Zhang et al. , 2010 KLK10 exon 3 hypermethylation is linked to gene expression in non-small cell lung cancers and is an independent prognostic biomarker of advanced and lymph node metastatic disease. Kobayashi et al. , 2011 KLK10 5 ′ UTR hypermethylation in prostate cancer tissues has been observed using a methylation microarray platform. Wong et al. , 2011 KLK1 methylation is associated with the downregulation of the gene in lung carcinoma cells. Chou et al. , 2011 The KLK13 promoter CpG island is hypomethylated in high-invasive lung cancer cell lines compared to normal lung cells.
(B) KLK regulation by histone modifi cations Kang et al. 2004 ; Jia et al. 2006 Activation of the KLK2 and KLK3 genes is associated with accumulation of lysine 9 and 14 di-acetylation in histone H3, increased phosphorylation of serine 10 in H3 and increased di-and tri-methylation of lysine 4 in H3 in androgen-sensitive prostate cancer cell line. Pampalakis and Sotiropoulou , 2006a ; Pampalakis et al. , 2009 Trichostatin A leads to increase in histone H4 acetylation and KLK6 expression in breast cancer cell lines.
(C) KLK regulation by miRNAs Chow et al. , 2008 Numerous miRNAs are predicted to target KLKs. Moreover, the same KLK can be a target of more than one miRNA, and each miRNA can target more than one KLK . Yousef , 2008 3 ′ UTR luciferase assay confi rms that the miRNA let-7f decreases KLK6 and KLK10 protein levels in breast cancer cell lines. White et al. , 2010b 3 ′ UTR luciferase assay confi rms that let-7f, miR-224 and mR-516a, each target KLK 10 in ovarian and prostate cancer cell lines. White et al. , 2010a The miRNA miR-224 targets KLK 1 in HEK-293 cells while let-7f targets KLK 10 in kidney cancer cell line. White, 2012 Transfection of miR-330, miR-331-3p and miR-143 into prostate cancer cell lines alters the expression of predicted target KLKs.
a dose-dependent increase in histone H4 acetylation and KLK6 expression was observed. This was accompanied by the presence of the CREB-binding protein co-activator and departure of MeCP2 repressor from the KLK 6 promoter. The role of DNA methylation in combination with histone modifi cations in the transcriptional activity of the KLK 6 gene was also investigated by combined treatment of MDA-MB-231 with trichostatin A and 5-aza-dC and resulted in synergistic activation of KLK 6. Table 1B summarizes the studies showing epigenetic regulation of KLKs by histone modifi cation.
KLK regulation by miRNAs
Recent studies have shown that miRNAs can target KLKs. Using different miRNA target prediction algorithms, Chow et al. provided the fi rst evidence that many miRNAs are predicted to target KLKs (Chow et al. , 2008 ) . In silico analyses revealed that about 60 % of known miRNAs are predicted to target KLKs. A total of 96 predicted KLK/miRNA interactions were detected by at least two prediction algorithms. KLK 10 was the most targeted KLK, followed by KLK 5, whereas KLK s 1, 3, 8 and 12 were not predicted as miRNA targets by more than one algorithm. Ten miRNAs were predicted to target more than one KLK. KLK s 2, 4, 5 and 10 were predicted to have multiple miRNA-targeting sites on their 3 ′ UTRs. A more recent analysis using the latest version of the miRBase miRNA database showed that the abovementioned fi gures remain comparable (our unpublished data).
It should be noted, however, that there is only a marginal overlap between the results of different target prediction algorithms and they all lack the optimal sensitivity and specifi city, and thus target validation is always needed to confi rm these interactions. Target validation can be performed using two independent approaches. The fi rst is to compare the protein (and/or mRNA) level of the KLK before and after transfection of the targeting miRNA. Using this approach, transfection of the let-7f miRNA was shown to decrease KLK6 and KLK10 protein levels in breast cancer lines (Yousef , 2008 ) . The second is to examine the effect of miRNA transfection on the luciferase signal of a plasmid containing the 3 ′ UTR of the KLK target (White et al. , 2010b ) .
Many KLK-miRNA interactions have been implicated in different cancers. White et al. compared KLK expression in ovarian cancer (assessed by compiling data from 14 published studies) to miRNA dysregulation in the same malignancy (compiled data from eight published studies) (White et al. , 2010b ) . A total of 99 miRNAs were documented to have altered expression in ovarian cancer. Target prediction analysis using three different programs showed that 62 of these miRNAs are predicted to target KLKs. All KLKs, except KLK14 , were predicted to be targets for ovarian cancerdysregulated miRNAs. There was also signifi cant concordance of expression profi les of the miRNAs and their KLK targets, i.e., downregulation of miRNAs is associated with upregulation of their KLK targets and vice versa . This was observed in 61 (49 % ) of the dysregulated miRNAs in ovarian cancer. They also showed that co-transfecting cells with a luciferase vector containing the KLK10 3 ′ UTR and either let-7f, miR-224 or mR-516a, led to decreased luciferase signal, confi rming that these miRNAs can target KLK 10. Additionally, they experimentally validated that these miRNAs have a negative effect on ovarian cancer cell proliferation through regulating KLK10 protein expression. Moreover, 25 miRNAs that are dysregulated in ovarian cancer were located in chromosomal hotspots that frequently showed chromosomal gain in ovarian cancer, suggesting the dysregulation of miRNAs in ovarian cancer may be partially explained by chromosomal aberrations.
The presence of a miRNA-KLK interaction was also recently documented for renal cell carcinoma (RCC). A recent study showed that 61 of the 117 miRNAs that are reported to be dysregulated in RCC were predicted to target KLKs (White et al. , 2010a ) . Of these, 31 are upregulated and 30 are downregulated. The most reported upregulated miRNAs, miR-122, miR-210, and miR-224, can potentially target KLK s 1, 2, 5, 7, 10, 11 and 15. miR-224 in particular, which was reported to be upregulated in three studies, was predicted to target KLK1 , KLK10 and KLK15 . miRNA let-7f was predicted to target KLK1 , KLK6 and KLK10 . Two of these targets were experimentally validated using two independent approaches. The dynamic interaction between miRNAs and kallikrienrelated peptidases. KLKs are miRNA targets. Evidence has shown that the same miRNA can target multiple KLKs (A), and that the same KLK can be a target of multiple miRNAs (B). KLKs are also proposed to control miRNAs, either by acting as on their promoters (C), or by ' consuming ' the amount of miRNA in a cell (D). It was also recently hypothesized that genes can cross-talk using the miRNA alphabet (E). There is also an interaction between miRNAs and epigenetic changes. Epigenetic regulation can affect miRNA gene expression (F), and miRNAs can also target genes responsible for epigenetic changes, which in turn affects KLK expression (G).
Transfection of miR-224 in the HEK-293 cell line resulted in decreased KLK1 protein. Also using a luciferase assay, KLK10 was shown to be a target of let-7f in the ACHN kidney cancer cell line. This study reported important observations: the same KLK can be a target of more than one miRNA, and each miRNA can target more than one KLK (Figure 1 A and B) .
More recently, the miRNA-KLK axis of interaction was recognized as a new dimension in the pathogenesis of prostate cancer. miRNAs dysregulated in prostate cancer were examined by comparing miRNA expression between normal and cancerous tissues from the same patient. A total of 55 miRNAs dysregulated in prostate cancer were predicted to target KLKs, with seven miRNAs (miR-1, miR-140, miR-143, miR-17-5p, miR-21, miR-24 and miR-331-3p ) that could target more than one KLK. The correlation between KLK and miRNA expression was examined in matched prostate cancer and normal fresh frozen tissue pairs from the same patient by quantitative reverse transcription polymerase chain reaction (RT -PCR) and showed that there was an inverse correlation pattern in the expression of miRNAs and their target KLKs (White et al. , 2012 ) . The effect of miRNAs on KLK protein expression was also tested using prostate cancer cell line models. Transfection of miR-330 and miR-143 resulted in alteration of the levels of predicted KLK targets (White, 2012) .
A negative association was also recently noted between miR-224 expression and KLK10 (unpublished data). By transfecting miR-331-3p and miR-143 into a prostate cancer cell line, there was decreased expression of targets KLK4 and KLK10, respectively, and decreased cellular growth was also observed (White, 2012) . Table 1C summarizes the studies showing epigenetic regulation of KLKs by miRNAs.
Future perspectives Epigenetic modifi cations as cancer biomarkers
Epigenetic modifi cations are considered attractive biomarkers for early detection of cancer partly because they can be assessed in body fl uids of individuals with cancer (Sawan and Herceg , 2010 ) . Techniques for detection of DNA methylation changes in body fl uids have already been developed (Vaissiere et al. , 2009 ) . The presence of free nucleosomes in plasma (Rumore and Steinman , 1990 ; Chan et al. , 2003 ) also suggests that histone modifi cations may be detected and used as useful biomarkers in predicting clinical outcomes (Deligezer et al. , 2008 ; Sawan and Herceg , 2010 ) . Studies of histone modifi cations in cancer demonstrate that different histone modifi cations can be used as a biomarker for early diagnosis of cancer and may also be powerful prognostic predictors (Fraga et al. , 2005 ; Barlesi et al. , 2007 ; Van Den Broeck et al. , 2008 ; Seligson et al. , 2009 ; Ellinger et al. , 2010 ; Manuyakorn et al. , 2010 ) .
As we advance in our understanding of the miRNA-KLK axis of interaction, we realize that this relationship is more complex than previously thought (Figure 1 ). On the one hand, KLKs can represent direct or indirect targets of miRNAs dysregulated in different diseases. KLKs, on the other hand, can also be responsible for regulating the expression levels of miRNAs. This can be achieved through different mechanisms. Some KLKs may be able to act as transcriptional factors that can control miRNA promoters ( Figure 1C ). Recent studies have documented KLK expression in the nucleus, in support of this hypothesis (Xi et al. , 2004 ; Dong et al. , 2005 ) . Also it was recently hypothesized that target genes, including KLK s, can also control miRNA function. This can be explained by the fact many genes are competing for the same limited pool of miRNAs, and thus the dysregulation of some KLKs may lead to consumption of the miRNA capacity ( Figure 1D ). miRNAs can also provide clues to the function of the many splice variants identifi ed for the KLK gene family (Yousef et al. , 2004 ) , and the KLK pseudogenes . Recently, the competing endogenous RNA hypothesis states that genes, (for example the KLK s in our case), can communicate with each other through the letters of a new alphabet, which is the small non-coding RNAs including miRNAs (Salmena et al. , 2011 ) (Figure 1E ). Especially in cases of genes with a high degree of homology in their 3 ′ UTR that contains miRNA response elements, the dysregulation of one gene can infl uence the stability and protein translation of another gene by altering the amount of available miRNAs. To add to the complexity of the miRNA-KLK axis, it has been shown recently that miRNAs can also affect promoters and coding regions of their targets (Place et al. , 2008 ; Iorio et al. , 2010 ) (Figure 1F and G).
Epigenetic modifi cations as a target for therapy
The precise understanding of how epigenetic silencing of tumor-suppressor genes occurs will surely lead to the development of alternative chemotherapies (Ballestar and Esteller , 2005 ) . The fact that in contrast to genetic changes, epigenetic alterations including histone modifi cations are reversible in nature, may provide the basis for development of new therapeutic and prevention approaches targeting aberrant histone modifi cations (Sawan and Herceg , 2010 ) . Many epigenetic therapies targeting epigenetic alterations have been recently developed. These include DNMT and HAT inhibitors, both of which aim to reactivate epigenetically silenced tumor suppressors, DNA repair genes, and other cancer-associated genes (Egger et al. , 2004 , Villar-Garea and . A number of agents altering histone modifi ers have been discovered and are currently in clinical trials (Egger et al. , 2004 ) . The toxic side effects of these emerging therapeutic agents will have to be addressed (Sawan and Herceg , 2010 ) .
miRNA-based cancer gene therapy offers the theoretical appeal of simultaneously targeting multiple gene networks that are controlled by a single, aberrantly expressed miRNA (Tong and Nemunaitis , 2008 ; White et al. , 2010a ) . Reconstitution of tumor-suppressor miRNAs or sequence-specifi c knockdown of oncogenic miRNAs has produced favorable antitumor outcomes in experimental models and are now being tested for therapeutic applications in different cancers (Garzon et al. , 2006 ; White et al. , 2010a ). An inherent diffi culty is the need for target validation. The presence of an indirect effect should be always considered and might be very diffi cult to exclude experimentally. Another challenge is the fact that the same miRNA can have multiple targets that might not be easy to control for. One solution to this might be the use of highthroughput target validation by quantitative mass spectrometry analysis coupled with bioinformatics and luciferase assay confi rmations. Also, it should be taken into consideration that the miRNA regulatory effect on KLKs is a complex and dynamic process with positive and negative feedback loops existing, and it is the net outcome of these interactions that controls KLK expression (Peter , 2010 ) . Finally, it should be noted that miRNAs do not usually cause a dramatic, but rather a moderate, effect on the expression of their targets.
